• 1
    Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 20316.
  • 2
    Vandesompele J,Baudis M,De Preter K,Van Roy N,Ambros P,Bown N,Brinkschmidt C,Christiansen H,Combaret V,Lastowska M,Nicholson J,O'Meara A, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005; 23: 228099.
  • 3
    Bown N,Cotterill S,Lastowska M,O'Neill S,Pearson AD,Plantaz D,Meddeb M,Danglot G,Brinkschmidt C,Christiansen H,Laureys G,Speleman F, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 195461.
  • 4
    Lastowska M,Van Roy N,Bown N,Speleman F,Lunec J,Strachan T,Pearson AD,Jackson MS. Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. Genes Chromosomes Cancer 1998; 23: 11622.
  • 5
    Schleiermacher G,Raynal V,Janoueix-Lerosey I,Combaret V,Aurias A,Delattre O. Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes Cancer 2004; 39: 14350.
  • 6
    Van Roy N,Cheng NC,Laureys G,Opdenakker G,Versteeg R,Speleman F. Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma. Eur J Cancer 1995; 31A: 5305.
  • 7
    Michels E,Vandesompele J,Hoebeeck J,Menten B,De Preter K,Laureys G,Van Roy N,Speleman F. Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints. Cytogenet Genome Res 2006; 115: 27382.
  • 8
    Spitz R,Oberthuer A,Zapatka M,Brors B,Hero B,Ernestus K,Oestreich J,Fischer M,Simon T,Berthold F. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006; 45: 113042.
  • 9
    Stallings RL,Nair P,Maris JM,Catchpoole D,McDermott M,O'Meara A,Breatnach F. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 2006; 66: 367380.
  • 10
    Michels E,Vandesompele J,De Preter K,Hoebeeck J,Vermeulen J,Schramm A,Molenaar J,Menten B,Marques B,Stallings R,Combaret V,Devalck C, et al. ArrayCGH based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007; 46(12): 10981108.
  • 11
    Menten B,Pattyn F,De Preter K,Robbrecht P,Michels E,Buysse K,Mortier G,De Paepe A,van Vooren S,Vermeesch J,Moreau Y,De Moor B, et al. arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics 2005; 6: 124.
  • 12
    De Preter K,Vandesompele J,Heimann P,Yigit N,Beckman S,Schramm A,Eggert A,Stallings RL,Benoit Y,Renard M,De Paepe A,Laureys G, et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006; 7: R84.
  • 13
    Van Roy N,Laureys G,Cheng NC,Willem P,Opdenakker G,Versteeg R,Speleman F. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994; 10: 10314.
  • 14
    Berwanger B,Hartmann O,Bergmann E,Bernard S,Nielsen D,Krause M,Kartal A,Flynn D,Wiedemeyer R,Schwab M,Schafer H,Christiansen H, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002; 2: 37786.
  • 15
    Oberthuer A,Berthold F,Warnat P,Hero B,Kahlert Y,Spitz R,Ernestus K,Konig R,Haas S,Eils R,Schwab M,Brors B, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24: 50708.
  • 16
    Bussey KJ,Kane D,Sunshine M,Narasimhan S,Nishizuka S,Reinhold WC,Zeeberg B,Ajay W,Weinstein JN. MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol 2003; 4: R27.
  • 17
    Meddeb M,Danglot G,Chudoba I,Venuat AM,Benard J,Avet-Loiseau H,Vasseur B,Le Paslier D,Terrier-Lacombe MJ,Hartmann O,Bernheim A. Additional copies of a 25 Mb chromosomal region originating from 17q23.1–17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer 1996; 17: 15665.
  • 18
    Savelyeva L,Corvi R,Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 1994; 55: 33440.
  • 19
    Vandesompele J,Speleman F,Van Roy N,Laureys G,Brinskchmidt C,Christiansen H,Lampert F,Lastowska M,Bown N,Pearson A,Nicholson JC,Ross F, et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol 2001; 36: 510.
  • 20
    Vandesompele J,Van Roy N,Van Gele M,Laureys G,Ambros P,Heimann P,Devalck C,Schuuring E,Brock P,Otten J,Gyselinck J,De Paepe A, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 1998; 23: 14152.
  • 21
    Lastowska M,Cullinane C,Variend S,Cotterill S,Bown N,O'Neill S,Mazzocco K,Roberts P,Nicholson J,Ellershaw C,Pearson AD,Jackson MS. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001; 19: 308090.
  • 22
    Carr J,Bell E,Pearson AD,Kees UR,Beris H,Lunec J,Tweddle DA. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006; 66: 213845.
  • 23
    Emanuel BS,Shaikh TH. Segmental duplications: an “expanding” role in genomic instability and disease. Nat Rev Genet 2001; 2: 791800.
  • 24
    Lastowska M,Cotterill S,Bown N,Cullinane C,Variend S,Lunec J,Strachan T,Pearson AD,Jackson MS. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 2002; 34: 42836.
  • 25
    Gorlich D,Kostka S,Kraft R,Dingwall C,Laskey RA,Hartmann E,Prehn S. Two different subunits of importin cooperate to recognize nuclear localization signals and bind them to the nuclear envelope. Curr Biol 1995; 5: 38392.
  • 26
    Giri DK,Ali-Seyed M,Li LY,Lee DF,Ling P,Bartholomeusz G,Wang SC,Hung MC. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 2005; 25: 1100518.
  • 27
    Lo HW,Ali-Seyed M,Wu Y,Bartholomeusz G,Hsu SC,Hung MC. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 2006; 98: 157083.
  • 28
    Lacombe ML,Milon L,Munier A,Mehus JG,Lambeth DO. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000; 32: 24758.
  • 29
    Lascu I,Gonin P. The catalytic mechanism of nucleoside diphosphate kinases. J Bioenerg Biomembr 2000; 32: 23746.
  • 30
    Steeg PS,Bevilacqua G,Kopper L,Thorgeirsson UP,Talmadge JE,Liotta LA,Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 2004.
  • 31
    Hartsough MT,Steeg PS. Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr 2000; 32: 3018.
  • 32
    Hailat N,Keim DR,Melhem RF,Zhu XX,Eckerskorn C,Brodeur GM,Reynolds CP,Seeger RC,Lottspeich F,Strahler JR, et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 1991; 88: 3415.
  • 33
    Chen QR,Bilke S,Wei JS,Greer BT,Steinberg SM,Westermann F,Schwab M,Khan J. Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma. Genes Chromosomes Cancer 2006; 45: 85662.